FDA Approves Takeda's Orexin-Targeting Narcolepsy Drug
Takeda's oveporexton, marketed as Orzeyful, received FDA approval for adult narcolepsy type 1, becoming the first therapy to directly restore orexin signaling. The twice-daily tablet improved daytime sleepiness, cataplexy, and other symptoms in trials, and had previously earned Breakthrough Therapy and Priority Review designations.
Expanded Detail
EXPANDED:
The approval of oveporexton (Orzeyful) represents a distinct shift in narcole
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
UniQure seeks FDA and UK approval for Huntington's gene therapy AMT-130 · Drug development
Roivant wins FDA approval for first oral dermatomyositis treatment · Drug development
FDA approves Ionis' RNA-based treatment for rare Alexander disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA Neurology Digest: August 2026.” Browse more stories.